Sort
16,179 grants matching “malaria”
Regulatory Support Services
$12,854,530John Tierney · National Institute Of Allergy And Infectious Diseases · ZID · FY2024 · AI
Core D: Medicinal Chemistry Core
$12,760,250Timothy M Willson · Univ Of North Carolina Chapel Hill · U19 · FY2022 · AI
CoVPN 3008 2022-2023
$12,647,369Peter B. Gilbert · Fred Hutchinson Cancer Center · UM1 · FY2023 · AI
Vanderbilt Vaccine and Treatment Evaluation Unit
$12,509,936Clarence Buddy Creech · Vanderbilt University Medical Center · UM1 · FY2020 · AI
Advancing genomic, transcriptomic and functional approaches to combat globally important and emerging pathogens
$12,121,843Daniel E Neafsey · Broad Institute, Inc. · U19 · FY2024 · AI
A once-weekly oral methadone for maintenance therapy for opioid use disorder
$11,699,793Richard Scranton · Lyndra Therapeutics, Inc. · UH3 · FY2021 · DA
Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG)
$11,669,860David S Stephens · Emory University · UM1 · FY2022 · AI
DCTD Biopharmaceutical Development
$11,541,306Larry Arthur · Science Applications International Corp · N01 · FY2009 · CA
Regulatory Support Services
$11,311,037Jerome Pierson · National Institute Of Allergy And Infectious Diseases · ZID · FY2017 · AI
Regulatory Support Services
$11,269,404Jerome Pierson · National Institute Of Allergy And Infectious Diseases · ZID · FY2019 · AI
COVID-19 Supplement #3 Moderna Trial
$11,154,495Daniel F. Hoft · Saint Louis University · UM1 · FY2020 · AI
Manufacturing of Novel Adenovirus Prime-Boost HIV-1 Vaccine
$10,842,162Jaap Goudsmit · Beth Israel Deaconess Medical Center · U19 · FY2009 · AI
IMPROVEMENT OF TAFENOQUINE RADICAL CURE BY COMBINATION WITH SJ733, A NOVEL ATP4 INHIBITOR, FOR TREATMENT OF MALARIA
$10,606,583University Of Kentucky Research Foundation, The · · FY2025 · Defense Health Agency
THIS RESEARCH PROJECT IS A CONTINUATION OF THE JOINT COLLABORATION AT ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES (AFRIMS) OF THE 1977 ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES AGREEMENT. RESEARCH ACTIVITIES WILL INCLUDE BASIC RESEARCH, EPIDEMIOLOGY, AND FIELD TESTING OF VACCINES, DIAGNOSTIC TESTS, AND TREATMENTS FOR TROPICAL DISEASES. U.S. WARFIGHTER THREATS WITH A MAJOR FOCUS ON VECTOR CONTROL, MALARIA, HUMAN IMMUNODEFICIENCY VIRUS (HIV), VECTOR-BORNE VIRUSES, DIARRHEAL ILLNESS ANTIMICROBIAL RESISTANCE, WOUND INFECTIONS AND RESPIRATORY VIRUSES. CORRECTING FUNDING CODE FROM HT0989 TO HT0960 PER CONTRACT.
$10,226,017Afrims Thai Component · · FY2025 · Defense Health Agency
University of Washington Vaccine and Treatment Evaluation Unit
$9,616,028Anna Wald · University Of Washington · UM1 · FY2020 · AI
DCTD Biopharmaceutical Development
$9,577,323David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2012 · CA
DCTD Biopharmaceutical Development
$9,525,000Larry Arthur · Leidos Biomedical Research, Inc. · N01 · FY2010 · CA
Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)
$9,214,781Mark Joseph Mulligan · New York University School Of Medicine · UM1 · FY2020 · AI
Infectious Diseases Research Technologies Core - Bethesda
$9,005,342Robert Hohman · National Institute Of Allergy And Infectious Diseases · ZIC · FY2010 · AI
Large-Scale Sequencing and Assembly of the A. gambiae
$8,915,748Applera Corporation · U01 · FY2001 · AI
TULANE NATIONAL PRIMATE RESEARCH CENTER
$8,796,547Tulane University Of Louisiana · P51 · FY2003 · RR
CoVPN 5001 A Prospective Study of Acute Immune Responses to SARS-CoV-2 Infection LC 3
$8,696,751Margaret Juliana McElrath · Fred Hutchinson Cancer Center · UM1 · FY2022 · AI
Malaria Transmission Blocking Vaccine Discovery
$8,566,689Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG)
$8,427,829David S Stephens · Emory University · UM1 · FY2025 · AI
Infectious Diseases Research Technologies Core - Bethesda
$8,422,285Robert Hohman · National Institute Of Allergy And Infectious Diseases · ZIC · FY2009 · AI